EC Number | Application | Comment | Organism |
---|---|---|---|
3.2.1.50 | medicine | a minimum threshold of about 20% of wild type residual enzyme activity levels is required to completely prevent accumulation of heparan sulfate in Sanfilippo syndrome type B patient fibroblasts. BMN 250 cellular uptake under very limiting and transient exposure conditions occurs in sufficient amounts to reach this threshold | Homo sapiens |
EC Number | Cloned (Comment) | Organism |
---|---|---|
3.2.1.50 | expressed in CHO cells | Homo sapiens |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.2.1.50 | lysosome | - |
Homo sapiens | 5764 | - |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.2.1.50 | Homo sapiens | P54802 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.2.1.50 | microglia | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.2.1.50 | 4-methylumbelliferyl N-acetyl-alpha-D-glucosaminide + H2O | - |
Homo sapiens | 4-methylumbelliferone + N-acetyl-alpha-D-glucosamine | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.2.1.50 | BMN 250 | tralesinidase alfa, a fusion protein of lysosomal alpha-N-acetylglucosaminidase with insulin-like growth factor 2 | Homo sapiens |
3.2.1.50 | NAGLU | - |
Homo sapiens |
EC Number | General Information | Comment | Organism |
---|---|---|---|
3.2.1.50 | malfunction | enzyme mutations cause the Sanfilippo B syndrome which leads to severe neurodegenerative disease and early death | Homo sapiens |